MARKET

ALMS

ALMS

Alumis Inc
NASDAQ
10.45
-0.52
-4.74%
After Hours: 10.45 0 0.00% 16:41 12/29 EST
OPEN
10.88
PREV CLOSE
10.97
HIGH
11.17
LOW
10.44
VOLUME
578.84K
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
2.760
MARKET CAP
1.09B
P/E (TTM)
-2.7111
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALMS last week (1222-1226)?
Weekly Report · 12h ago
How Investors May Respond To Alumis (ALMS) Joining The S&P Pharmaceuticals Select Industry Index
Simply Wall St · 6d ago
Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 12/22 13:05
Weekly Report: what happened at ALMS last week (1215-1219)?
Weekly Report · 12/22 09:20
Assessing Alumis (ALMS) Valuation After S&P Pharma Index Inclusion and Reinforced Analyst Optimism
Simply Wall St · 12/22 01:13
Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Canfor (OtherCFPZF)
TipRanks · 12/19 01:50
Alumis Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/18 16:37
Alumis Price Target Raised to $20.00/Share From $14.00 by HC Wainwright & Co.
Dow Jones · 12/18 16:37
More
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.

Webull offers Alumis Inc stock information, including NASDAQ: ALMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALMS stock methods without spending real money on the virtual paper trading platform.